‘Clearly different’: Cognitive effects vary by treatment in advanced prostate cancer

CHICAGO — The cognitive effects men with advanced prostate cancer experience during treatment may vary based on the therapy they receive, according to randomized phase 2 trial results presented at ASCO Annual Meeting.An analysis of more than 100 men showed those randomly assigned to darolutamide (Nubeqa, Bayer) experienced significantly less cognitive decline over 24 weeks than those